Background {#Sec1}
==========

Diabetes mellitus is a major risk factor for heart failure (HF), especially HF with preserved ejection fraction (HFPEF) development \[[@CR1], [@CR2]\]. Diabetes and HF commonly coexist, and together these conditions are associated with increased morbidity and mortality compared with either condition alone \[[@CR3]--[@CR7]\]. A recent study in Olmsted County, MN, USA, has shown that the prevalence of diabetes in HF patients has increased markedly over time (3.8 % per year) \[[@CR8]\]. An angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) is effective in treating HF as well as reducing insulin resistance in patients with diabetes \[[@CR9]\]. Other therapeutic strategies are lacking the same level of effectiveness. Studies have shown that elevated HbA1c is a marker of increased risk of developing HF and, therefore, poor glycemic control may be causally related to the development of HF \[[@CR10], [@CR11]\]. However, the optimal treatment of hyperglycemia in patients with diabetes to reduce the progression of HF has not been well studied.

Recent studies have shown that dipeptidyl peptidase-4 inhibitor (DPP-4i), which increases the circulating glucagon-like peptide-1 (GLP-1) level, attenuates postprandial hyperglycemia and may have cardio-protective effects \[[@CR12]--[@CR14]\]. In a diabetic rat model, Shigeta et al. \[[@CR15]\] demonstrated that DPP4 inhibition reverses left ventricular (LV) diastolic dysfunction via membrane-bound DPP4/stromal cell-derived factor-1α-dependent local actions on angiogenesis and circulating DPP4/GLP-1-mediated inotropic actions. Using HF-model rats, dos Santos et al. \[[@CR16]\] reported that sitagliptin (40 mg/kg) administered for 6 weeks exhibited a significant improvement in cardiac contraction and reduction in LV end-diastolic pressure and chamber stiffness. Small pilot studies of GLP-1 have shown potential promise in the treatment of HF patients \[[@CR17], [@CR18]\]. However, it remains unknown whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, whether the effect is attributable to the attenuation of postprandial hyperglycemia or to the direct cardiac effect of DPP-4i.

Methods {#Sec2}
=======

We conducted a randomized, prospective, open-label, multicenter study to compare the effects of sitagliptin, a DPP-4 inhibitor, and voglibose, an alpha GI, on LV diastolic function. The assessment was done by Doppler echocardiography in patients with type 2 diabetes at 13 sites between January 2011 and January 2013.

Study population {#Sec3}
----------------

Our study population consisted of outpatients with type 2 diabetes from 20 to 85 years of age with LV diastolic dysfunction (LV ejection fraction \>50 %, mitral annular early diastolic velocity (e') \<8 cm/s or the ratio of mitral inflow velocity to e' velocity (E/e' ratio) \>15). These patients had not achieved the targets for glycemic control with diet, exercise, sulfonylurea, metformin or pioglitazone treatments. We recruited 100 patients with 50 receiving sitagliptin (50 mg/day) treatment and 50 voglibose (0.6 mg/day). The doses of the two drugs used in this study are the recommended therapeutic doses for Japanese patients who are covered by the Japanese National Health Insurance.

The exclusion criteria were: patients being treated with insulin, alpha GI or glinide; and/or exhibited any of the following: type 1 diabetes, HbA1c ≥9.0 % (75 mmol/mol), systolic blood pressure ≥160 mmHg and serum creatinine ≥1.5 mg/dL at baseline, myocardial infarction (MI) or stroke within the previous 24 weeks, significant LV hypertrophy at baseline (LV wall thickness ≥13 mm), atrial fibrillation at baseline, and significant valve diseases (more than or equal to moderately severe valve diseases). The study protocol was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and of each hospital. Written informed consent was obtained from all patients before any study procedure.

Study protocol {#Sec4}
--------------

The patients were followed for at least 8 weeks to observe that the treatment goal by diet, exercise, sulfonylurea, metformin or pioglitazone was not being achieved. The patients were prospectively and randomly assigned to additional treatment with either sitagliptin (50 mg/day) or voglibose (0.6 mg/day) for at least 24 weeks (Fig. [1](#Fig1){ref-type="fig"}). We chose a stratified block randomization. Stratified block randomization was computer-generated and done by use of a web-based system (Nouvelle Place Inc. \[<http://www.n-place.co.jp/>\]). Patients were stratified according to age (≥ or \< 65 years old), HbA1c (≥ or \< 7 %), e' (≥ or \< 6.0 cm/s), and combined use of thiazolidinediones.Fig. 1The study's workflow. Twenty patients were excluded including 6 who were lost to follow-up, 1 who declined to participate and 13 for protocol violation (not meeting inclusion criteria, 12 patients; LVEF \< 50 %, 1; under medical treatment with high-dose sulfonylurea). The follow-up study was completed in 77 (77 %) of the patients; 38 received sitagliptin and 39 voglibose

Standard echocardiography was performed at the baseline and after 24 weeks of treatment. From the mitral flow velocity pattern, measurements were taken of peak velocities of E and A waves, the ratio of their peak velocities (E/A ratio) and deceleration time of the E wave. Spectral pulsed-wave Doppler tissue interrogation of longitudinal mitral annular velocity was recorded throughout the cardiac cycle at the septal annulus in the apical four-chamber view. The peaks of myocardial systolic apically directed velocity (s') and early diastolic velocity (e') were measured.

Additional exploratory analyses including changes in the chamber dimensions and LV ejection fraction were assessed. LV mass was measured by using the American Society of Echocardiography-recommended formula and the end-systolic left atrial volume was measured by using the ellipsoid model \[[@CR19]\]. Both values were indexed with body surface area in m^2^. All echocardiographic studies were done when patients were clinically stable on treatment.

Measurements of biochemical parameters {#Sec5}
--------------------------------------

The following parameters were measured at baseline and after 24 weeks of treatment: complete blood count, liver function test including measurement of AST, ALT and LDH, renal function test including measurement of BUN, creatinine, Na, K and Cl, HbA1c, gastric inhibitory peptide (GIP), GLP-1, C-peptide, CD34, lipid profile including total cholesterol, triglyceride, and high-density lipoprotein (HDL-C), adiponectin, oxidative stress markers including malondialdehyde-modified low density lipoprotein (MDA-LDL) and urine 8-hydroxy-2′-deoxyguanosine (8-OHdG), inflammatory markers including high-sensitive C-reactive protein (hs-CRP) and pentraxin-3 (PTX-3), and estimated glomerular filtration rate (eGFR). HbA1c levels were measured using high-performance liquid chromatography. The number of CD34+ cells was determined by flow cytometry using fluorescein isothiocyanate-labeled CD45 and phycoerythrin (PE)-labeled CD34 antibodies (BD Biosciences, Franklin Lakes, NJ, USA). eGFR (mL/min/1.73 m^2^) was determined by the modified Modification of Diet and Renal Disease study formula (MDRD) for Japanese: eGFR = 194 × (age-0.287) × (serum creatinine-1.094) × (0.739 if female). Brain natriuretic peptide (BNP) concentrations were measured using a commercially available specific radioimmunoassay for human BNP (Shiono RIA BNP assay kit, Shionogi Co., Ltd., Osaka, Japan), respectively. Antihypertensive, antihyperlipidemic and antidiabetic drugs were not changed and anti-oxidant drugs including vitamin C and E were not added throughout the study period.

Endpoints {#Sec6}
---------

The primary endpoints were changes in e' and E/e' ratio from baseline to the end of follow-up. The secondary efficacy measures included changes in glucose, HbA1c, GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress markers including MDA-LDL and 8-OHdG, inflammatory markers including hs-CRP and PTX-3 and eGFR, and any adverse events.

Statistical analysis {#Sec7}
--------------------

All of the results are expressed as mean ± SD or as proportions (%). We assumed that e' increased by 1.0 cm/s in the sitagliptin group and 0.2 cm/s in the voglibose group with a standard deviation of 1.5 cm/s \[[@CR20]\]. A minimum sample size of 57 participants in each group was required to detect statistical differences in e' with a power of 80 % and α error of 5 %. The effects of sitagliptin and voglibose on LV diastolic function were compared using a paired *t*-test. Differences in age, sex, weight, body mass index and blood pressure were compared using the Student's *t*-test. Categorical variables were compared using *χ*^2^ test and Fisher's exact test when appropriate. Differences in secondary efficacy measures between baseline and 24 weeks were compared using a paired *t*-test. A value of p \< 0.05 was set as the threshold for significance. The effects of sitagliptin and voglibose on LV diastolic function (e' and E/e' ratio) were assessed by analysis of covariance (ANCOVA) after adjustment for covariates that included baseline e' and E/e' ratio, age, sitagliptin/voglibose use and concomitant thiazolidinedione use. Multivariate analysis of factors related to changes from baseline to 24 weeks in e' and E/e' ratio levels was performed. All analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec8}
=======

Baseline characteristics {#Sec9}
------------------------

One hundred patients (59 men and 41 women, aged 67.1 ± 9.6 years) with type 2 diabetes were enrolled in this study. Fifty patients received sitagliptin (50 mg/day) treatment and 50 patients received voglibose (0.6 mg/day) treatment. Twenty patients were excluded including 7 who were lost to follow-up and 13 for protocol violation (not meeting inclusion criteria, 6 patients;LV ejection fraction \<50 %, 1; under medical treatment with high-dose sulfonylurea.). The follow-up study was completed in 80 (80 %) of the patients; 40 received sitagliptin and 40 voglibose (Fig. [1](#Fig1){ref-type="fig"}). Baseline clinical characteristics, including age, sex, body mass index and the type of antidiabetic and antihypertensive medication are shown in Table [1](#Tab1){ref-type="table"}. No patients died, developed cardiovascular events or were admitted to the hospital during the study.Table 1Baseline clinical characteristicsVariableSitagliptin n = 40Voglibose n = 40*P* valueAge, y67.8 ± 10.566.7 ± 9.80.654Women, n (%)20(50)14(35)0.258Diabetes duration, months (95 % CI)48(6-240)38.5(3-218)0.145Body mass index, kg/m227.7 ± 4.125.7 ± 4.30.038Abdominal girth, cm88.7 ± 14.385.9 ± 15.60.469Current smoking6(15)4(10)0.762Regular alcohol drinkers13(33)17(43)0.489NYHA functional classClass I, n (%)17(43)17(43)1.000Class II, n (%)23(58)22(55)Class III, n (%)0(0)1(3)Grades of Diastolic Dysfunction01 (2.6)3 (7.5)0.0987131 (79.5)34 (85.0)27 (17.9)3 (7.5)Diabetes complication+7(18)3(8)0.311Diabetic retinopathy4(10)2(5)0.675Diabetic nephropathy3(8)0(0)0.241Diabetic neuropathy2(5)0(0)0.494Hypertension37(93)32(80)0.193Hyperuricemia31(78)31(78)1.000Hyperlipidemia5(13)4(10)1.000Renal disturbance7(18)1(3)0.057Mean eGFR74.8 ± 21.770.5 ± 15.30.304Cerebrovascular disease3(8)1(3)0.615Myocardial infarction5(13)2(5)0.432Peripheral artery disease3(8)1(3)0.615Anti-diabetic drugsPioglitazone14(35)18(45)0.494Sulfonylurea6(15)3(8)0.481Metformin7(18)1(3)0.057α-GI1(3)0(0)1.000Antihypertensive drugsARB28(70)27(68)1.000Calcium channel blocker26(65)22(55)0.494Diuretics15(38)10(25)0.335Others11(28)10(25)1.000ACE-I2(5)3(8)α-blocker4(10)1(3)β-blocker6(15)4(10)αβ-blocker1(3)1(3)Aldosterone antagonist2(5)1(3)Antihyperlipidemic drugsStatins24(60)22(55)0.821Fibrate2(5)2(5)1.000Ezetimibe5(13)6(15)1.000Eicosapentaenoic acid5(13)2(5)0.432Antiplatelet agent10(25)12(30)0.803Nitrates1(3)1(3)1.000Allopurinol1(3)4(10)0.359Uricosuric agents0(0)1(3)1.000Values are means ± SD, number of patients (%), or median (95 % confidencel Interval). The continuous variables were compared using Student's *t*-test, the categorical variables were compared using Fisher's exact test, grades of diastolic dysfunction was compared using Cochran-Armitage trend test, and the duration of diabetes was compared using *the Wilcoxon rank sum test*

The primary endpoint {#Sec10}
--------------------

The e' velocity and E/e' ratio were comparable between the sitagliptin and voglibose groups at baseline. The e' velocity and E/e' ratio in both groups showed no changes between baseline and after a mean of 24 weeks (e': sitagliptin +0.2 ± 1.1 cm/s and voglibose +0.3 ± 0.9 cm/s; E/e': sitagliptin −0.3 ± 2.5 and voglibose −0.5 ± 2.3). There was also no difference in magnitude of the changes in e' velocity and E/e' ratio between the two groups (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Table 2Changes in e' velocity and E/e' ratio in the sitagliptin and voglibose groupVariableSitagliptin n = 40Voglibose n = 40Between-group differencee'Baseline at 0W5.6 ± 1.35.5 ± 1.1p = 0.664at 24W5.8 ± 1.35.8 ± 1.1p = 0.997Δe': 24W-0W0.2 ± 1.10.3 ± 0.9p = 0.702E/e'Baseline at 0W12.8 ± 4.311.6 ± 2.1p = 0.109at 24W12.4 ± 3.411.1 ± 2.7p = 0.060ΔE/e': 24W-0W-0.3 ± 2.5-0.5 ± 2.3p = 0.804Values are means ± SD*W* weeksFig. 2Changes in e' and E/e' between baseline and 24 weeks later. The e' velocity and E/e' ratio were comparable between sitagliptin and voglibose groups at baseline. The e' velocity and E/e' ratio showed no changes between baseline and a mean of 24 weeks later in both groups. There was also no significant difference in the magnitude of the changes in e' velocity and E/e' ratio between the two groups. e', mitral annular early diastolic velocity; E/e', ratio of mitral inflow velocity to e' velocity; W, weeks

The effects of sitagliptin and voglibose on LV diastolic function (e' and E/e' ratio) were assessed by ANCOVA after adjustment for covariates that included baseline e' and E/e' ratio, age, sitagliptin/voglibose use and concomitant thiazolidinedione use. ANCOVA demonstrated that pioglitazone use is an independent factor associated with changes in e' and E/e' ratio (Table [3](#Tab3){ref-type="table"}). Among patients not using pioglitazone, e\' increased and E/e' ratio decreased in both sitagliptin and voglibose groups (e': sitagliptin +0.5 ± 1.1 cm/s and voglibose +0.5 ± 0.9 cm/s; E/e': sitagliptin −1.0 ± 2.7 and voglibose −0.8 ± 2.4).Table 3Factors affecting e' and E/e' at week 24^a^Dependent variableIndependent variableEstimate95 % CI*P* valuee' (24W)e' (0W)0.5250.3090.742\<0.0001Sitagliptin/Voglibose-0.047-0.4550.3620.821Age --- yr-0.028-0.054-0.0030.032without/with TZD0.5470.1300.9650.011E/e' (24W)E/e' (0W)0.6150.4710.758\<0.0001Sitagliptin/Voglibose0.688-0.2391.6150.144Age --- yr0.024-0.0250.0720.334without/with TZD-1.411-2.339-0.4830.00395 % CIs and *P* values were calculated with the use of analysis of covariance (ANCOVA)^a^CI denotes confidence interval

Multivariate analysis of factors related to changes from baseline to 24 weeks in e' and E/e' ratio levels showed for e', without/with thiazolidinedione was not statistically significant only if adiponectin was added in the model, and for E/e', without/with thiazolidinedione was statistically significant for all models, which implies that without/with thiazolidinedione could be an independent factor associated with changes in the E/e' ratio (Table [4](#Tab4){ref-type="table"}).Table 4Multivariate analysis of factors related to changes from baseline to week 24 in e' and E/e' ratio levels^a^Modele' \[cm/s\]E/e'Change from baselineP value^b^R2Change from baselineP value^b^R2Beta (95 % CI)Beta (95 % CI)Model1---Primary model0.5000.609Baseline0.525 (0.309 to 0.742)\<.00010.615 (0.471 to 0.758)\<.0001Sitagliptin/Voglibose-0.047 (-0.455 to 0.362)0.82060.688 (-0.239 to 1.615)0.1436Age---yr-0.028 (-0.054 to -0.003)0.03170.024 (-0.025 to 0.072)0.3335Without/with TZD0.547 (0.130 to 0.965)0.0109-1.411 (-2.339 to -0.483)0.0034Model2---Add demographic values^b^0.5220.641Baseline0.520 (0.298 to 0.742)\<.00010.603 (0.456 to 0.750)\<.0001Sitagliptin/Voglibose-0.069 (-0.504 to 0.365)0.75090.683 (-0.271 to 1.636)0.1576Age---yr-0.025 (-0.052 to 0.002)0.07390.013 (-0.037 to 0.064)0.5964Female/Male0.243 (-0.195 to 0.681)0.2718-1.114 (-2.092 to -0.137)0.0261BMI (0W)0.033 (-0.019 to 0.084)0.2140-0.037 (-0.155 to 0.081)0.5306SBP (0W)-0.005 (-0.020 to 0.011)0.5454-0.002 (-0.036 to 0.031)0.8917Pulse (0W)-0.003 (-0.025 to 0.019)0.78820.022 (-0.028 to 0.071)0.3911Without/with TZD0.662 (0.216 to 1.108)0.0042-1.732 (-2.711 to -0.753)0.0007Model3---Add complications^b^0.5180.626Baseline0.487 (0.253 to 0.721)\<.00010.584 (0.425 to 0.744)\<.0001Sitagliptin/Voglibose0.018 (-0.426 to 0.462)0.93620.642 (-0.331 to 1.615)0.1922Age---yr-0.031 (-0.057 to -0.004)0.02280.030 (-0.020 to 0.081)0.2389Diabetes complication-0.395 (-1.038 to 0.247)0.22380.721 (-0.799 to 2.241)0.3473Hypertension0.202 (-0.410 to 0.814)0.5131-0.527 (-1.908 to 0.854)0.4491Hyperlipidemia0.219 (-0.317 to 0.755)0.4177-0.886 (-2.086 to 0.313)0.1450Renal disturbance-0.219 (-1.000 to 0.562)0.57800.277 (-1.453 to 2.007)0.7502Without/with TZD0.511 (0.068 to 0.954)0.0244-1.302 (-2.271 to -0.334)0.0092Model4---Add laboratory values^b^0.5250.642Baseline0.542 (0.314 to 0.770)\<.00010.615 (0.469 to 0.761)\<.0001Sitagliptin/Voglibose-0.127 (-0.568 to 0.314)0.56710.669 (-0.314 to 1.651)0.1790Age---yr-0.023 (-0.053 to 0.006)0.12200.029 (-0.027 to 0.084)0.3045WBC (0W)-0.000 (-0.000 to 0.000)0.70300.000 (-0.000 to 0.000)0.2013AST (0W)0.012 (-0.008 to 0.032)0.23980.003 (-0.040 to 0.046)0.8871BUN (0W)0.009 (-0.045 to 0.063)0.7380-0.019 (-0.139 to 0.101)0.7498Glucagon (0W)-0.001 (-0.012 to 0.010)0.8296-0.010 (-0.034 to 0.014)0.3929Adiponectin (0W)-0.017 (-0.049 to 0.016)0.3067-0.030 (-0.102 to 0.041)0.4020IVSTh (0W)-0.192 (-1.847 to 1.463)0.8175-1.323 (-5.000 to 2.353)0.4749Without/with TZD0.380 (-0.181 to 0.941)0.1808-1.675 (-2.916 to -0.434)0.0089Model5---Add adiponectin^c^0.5110.620Baseline0.516 (0.299 to 0.732)\<.00010.623 (0.480 to 0.766)\<.0001Sitagliptin/Voglibose-0.080 (-0.490 to 0.330)0.69910.587 (-0.344 to 1.519)0.2129Age---yr-0.025 (-0.051 to 0.001)0.06370.033 (-0.016 to 0.083)0.1858Adiponectin (0W)-0.018 (-0.047 to 0.011)0.2169-0.046 (-0.112 to 0.019)0.1610Without/with TZD0.388 (-0.099 to 0.876)0.1169-1.807 (-2.884 to -0.730)0.0013Model6---Remove TZD0.4930.560Baseline0.480 (0.266 to 0.695)\<.00010.624 (0.472 to 0.777)\<.0001Sitagliptin/Voglibose-0.067 (-0.481 to 0.347)0.74710.566 (-0.429 to 1.561)0.2605Age---yr-0.026 (-0.052 to 0.001)0.05800.025 (-0.028 to 0.078)0.3505Adiponectin (0W)-0.030 (-0.055 to -0.005)0.01870.010 (-0.050 to 0.070)0.7331^a^The analysis was performed in the full analysis set, with the use of analysis of covariance, WBC denotes white blood cell, AST aspartate transaminase, BUN blood urea nitrogen, IVSTh interventricular septum thickness, and TZD thiazolidinedione^b^Statistically significant variables (alpha = 0.05) were selected from measured demographics, complications and laboratory variables with the use of two sample t-tests, according to without/with TZD groups in the full analysis set^c^For e', without/with TZD was not statistically significant (alpha = 0.05) only if adiponectin was added in the model

Secondary efficacy measures {#Sec11}
---------------------------

The GLP-1 level increased from baseline to 24 weeks later in the sitagliptin group but not in the voglibose group (4.8 ± 4.7 pmol/L vs. 7.3 ± 5.5 pmol/L, p \< 0.05, respectively). The decreases in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group (−0.7 ± 0.6 % vs. −0.3 ± 0.4 %, p \< 0.005 and −1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p \< 0.05, respectively). There were no significant differences in the changes in C-peptide, lipid profile, oxidative stress marker and inflammatory marker between the two groups (Table [5](#Tab5){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). In only the sitagliptin group, and not the voglibose group, did the systolic blood pressure and LV septal wall thickness decrease 24 weeks later (135 ± 16 mmHg vs. 128 ± 10 mmHg and 0.97 ± 0.15 mm vs. 0.93 ± 0.14 mm, respectively) (Table [6](#Tab6){ref-type="table"}).Table 5Changes in secondary efficacy measures in the sitagliptin and voglibose groupVariableSitagliptinVogliboseBetween-group differenceMean ± SD*P* valueMean ± SD*P* value*P* valueGlucoseBaseline at 0W145 ± 58133 ± 420.304At 24W127 ± 26133 ± 270.35424W-0W-23 ± 600.0471 ± 430.9160.083HbA1cBaseline at 0W7.1 ± 0.76.9 ± 0.50.273At 24W6.4 ± 0.46.7 ± 0.50.02624W-0W-0.7 ± 0.6\<0.0001-0.3 ± 0.40.00040.002GIPBaseline at 0W191 ± 214159 ± 2110.517At 24W149 ± 161162 ± 1480.75924W-0W-21 ± 2260.3140.6 ± 1.60.0410.749CD34Baseline at 0W1.1 ± 0.70.9 ± 0.60.239At 24W1.1 ± 0.50.9 ± 0.70.16024W-0W0.1 ± 0.50.4350.0 ± 0.50.7720.430Total cholesterolBaseline at 0W184 ± 27185 ± 330.944At 24W178 ± 29183 ± 370.52224W-0W-3 ± 300.6030 ± 290.9910.709TriglycerideBaseline at 0W155 ± 107141 ± 740.486At 24W132 ± 62127 ± 720.80324W-0W-15 ± 940.391-13 ± 520.1900.905HDL-CBaseline at 0W51 ± 1256 ± 160.106At 24W52 ± 1453 ± 150.93024W-0W0.8 ± 7.90.551-3.6 ± 8.20.0100.021AdiponectinBaseline at 0W11.0 ± 8.313.3 ± 8.70.222At 24W11.7 ± 8.812.9 ± 7.30.52824W-0W0.5 ± 1.80.092-0.3 ± 2.90.5390.150MDA-LDLBaseline at 0W106 ± 34110 ± 370.658At 24W113 ± 34109 ± 360.59124W-0W9 ± 320.1181 ± 380.8600.3648-OHdGBaseline at 0W11.7 ± 7.913.5 ± 10.00.392At 24W11.4 ± 7.414.8 ± 14.60.22124W-0W-0.2 ± 10.00.9031.5 ± 16.90.5960.605hs-CRPBaseline at 0W3869 ± 90721358 ± 25110.099At 24W1933 ± 5101661 ± 6910.14724W-0W-1929 ± 67980.098-380 ± 11860.0590.186PTX-3Baseline at 0W1.8 ± 1.02.4 ± 2.70.206At 24W1.5 ± 0.81.6 ± 0.80.55724W-0W-0.3 ± 0.70.006-0.3 ± 1.20.1040.974e-GFRBaseline at 0W75 ± 2271 ± 150.304At 24W69 ± 1972 ± 160.41124W-0W-5 ± 120.0140 ± 90.9030.036BNP, pg/mlBaseline at 0W39 ± 4834 ± 350.600At 24W40 ± 4128 ± 240.16024W-0W1 ± 400.923-5 ± 220.1640.443*GIP* gastric inhibitory peptide, *GLP-1* glucagon-like peptide-1, *CD34* C-peptide, *MDA-LDL* malondialdehyde-modified low density lipoprotein, *8-OHdG* 8-hydroxy-2′-deoxyguanosine, *hs-CRP* high-sensitive C-reactive protein, *PTX-3*pentraxin-3, *eGFR* estimated glomerular filtration rate, *BNP* B-type natriuretic peptideFig. 3Changes in HbA1c, FBS, GLP-1 and body weight between baseline and 24 weeks later. The decreases in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group. GLP-1 level increased from baseline to 24 weeks later in the sitagliptin group but not in the voglibose group. FBS, fasting blood sugar; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; W, weeksTable 6Changes in hemodynamic and echocardiographic parameters in the sitagliptin and voglibose groupVariableSitagliptinVogliboseBetween-group differenceMean ± SD*P* valueMean ± SD*P* value*P* valueSBP, mmHgBaseline at 0W135 ± 16131 ± 130.180At 24W128 ± 10129 ± 150.85524W-0W-7 ± 170.022-2 ± 150.4960.184DBP, mmHgBaseline at 0W74 ± 1375 ± 100.818At 24W71 ± 1075 ± 110.10824W-0W-2 ± 140.3441 ± 100.7790.349Pulse, b.p.m.Baseline at 0W71 ± 1171 ± 100.903At 24W69 ± 1271 ± 110.48324W-0W-1 ± 120.6530 ± 120.8160.625Body weightBaseline at 0W69 ± 1067 ± 120.294At 24W68 ± 1167 ± 130.73624W-0W-1.3 ± 3.20.0180.4 ± 2.80.4330.020a', cm/sBaseline at 0W8.4 ± 1.69.0 ± 1.60.110At 24W8.1 ± 1.89.0 ± 1.60.03124W-0W-0.3 ± 1.70.3160.2 ± 1.40.4680.214s', cm/sBaseline at 0W6.6 ± 1.17.2 ± 1.20.019At 24W6.8 ± 1.47.0 ± 1.10.60924W-0W0.2 ± 1.40.398-0.2 ± 1.40.4120.237DctBaseline at 0W234 ± 41237 ± 390.769At 24W236 ± 42233 ± 430.76524W-0W1 ± 410.885-4 ± 350.5250.604E velocity, m/sBaseline at 0W68 ± 1662 ± 110.048At 24W69 ± 1463 ± 140.04724W-0W1 ± 100.5690 ± 120.8790.803A velocity, m/sBaseline at 0W82 ± 1979 ± 180.421At 24W80 ± 1974 ± 140.15024W-0W-1 ± 130.537-4 ± 100.0200.299E/A ratioBaseline at 0W0.9 ± 0.30.8 ± 0.20.424At 24W0.9 ± 0.20.9 ± 0.30.66824W-0W0.0 ± 0.20.4020.0 ± 0.20.1570.651Septal thickness, mmBaseline at 0W1.0 ± 0.20.9 ± 0.10.069At 24W0.9 ± 0.10.9 ± 0.10.50224W-0W0.0 ± 0.10.0150.0 ± 0.10.8760.083LVEF, %Baseline at 0W68 ± 771 ± 70.209At 24W68 ± 666 ± 90.17924W-0W0 ± 80.967-5 ± 80.0010.013LVMI, g/m2Baseline at 0W93 ± 2085 ± 180.085At 24W90 ± 1786 ± 180.23924W-0W-3 ± 130.1951 ± 140.5510.183LA volume index, ml/m2Baseline at 0W27.7 ± 5.926.1 ± 7.60.346At 24W27.7 ± 7.526.6 ± 6.30.50824W-0W0.3 ± 5.00.7340.8 ± 5.60.4480.733Urine albumin, mg/g/CrBaseline at 0W37 ± 6631 ± 410.603At 24W39 ± 9428 ± 500.53324W-0W-1 ± 500.889-5 ± 300.3390.723BUNBaseline at 0W17 ± 516 ± 50.760At 24W16 ± 316 ± 40.82424W-0W0 ± 30.7590 ± 40.7400.959

Adverse events {#Sec12}
--------------

Adverse events were observed in 2 patients in the sitagliptin group (hypoglycemia and liver dysfunction) and 4 patients in the voglibose group (diarrhea, edema and gastrointestinal symptoms) (Table [7](#Tab7){ref-type="table"}). Mild hypoglycemia of a patient in the sitagliptin group improved rapidly with dose reduction of sulfonylurea. Hospitalizations because of HF or cardiovascular events were not observed during the study period.Table 7Adverse eventsEventsSitagliptinVoglibosen = 40n = 402 cases (5.0)4 cases (10.0)Hypoglycemia1 (2.5)0 (0.0)Diarrhea0 (0.0)4 (10.0)Edema0 (0.0)3 (7.5)Gastrointestinal symptom0 (0.0)2 (5.0)Liver dysfunction1 (2.5)0 (0.0)Total events29Number of cases (%) is shown

Discussion {#Sec13}
==========

This study is the first randomized trial to compare the impact of glycemic control with sitagliptin and voglibose on LV diastolic function. Our study demonstrated that both sitagliptin and voglibose reduce HbA1c, but the magnitude of reduction of HbA1c was greater in the sitagliptin group and had a greater increase in the GLP-1 level. However, despite the improved glycemic control, the e' velocity and E/e' ratio did not show significant improvement after 24-week treatment with sitagliptin or voglibose. There was also no significant difference in the change in the e' velocity and E/e' ratio between the two groups.

The plasma BNP level, New York Heart Association (NYHA) functional class and the grades of diastolic function (ASE/EAE) did not show significant improvement in either group. Therefore, we conclude that sitagliptin and voglibose had no impact on e' velocity or E/e' ratio in patients with type 2 diabetes and impaired diastolic function.

Elevated HbA1c has been a marker of increased risk of developing HF in patients with diabetes \[[@CR10], [@CR11]\]. Poor glycemic control and associated hyperglycemia may be causally related to the development of HF by two mechanisms: (i) through promotion of atherosclerosis and the ensuing coronary artery disease \[[@CR21]\] and (ii) by development of a specific diabetic cardiomyopathy by direct damage to the heart muscle \[[@CR4], [@CR5]\]. However, studies examining treatment strategies of intensive glucose control, such as the UKPDS and the more recently completed ACCORD and ADVANCE studies have not shown statistically significant reductions in HF events in patients assigned to more intensive glucose control strategies when compared with those assigned to standard therapy \[[@CR22]--[@CR24]\]. In our study, the blood glucose level was lowered with sitagliptin and voglibose though the reduction of HbA1c was greater in the sitagliptin group, which also had an associated greater increase in the GLP-1 level. Reduction of body weight and systolic blood pressure was also found in the sitagliptin group. These apparently beneficial changes were not, however, associated with an increase in e' velocity or with a reduction in E/e' ratio in either groups.

Recently, the SAVOR-TIMI 53 trial showed that DPP-4i may increase the risk of HF \[[@CR25]\], which is of concern. In this trial, more patients in the saxagliptin group than in the placebo group were hospitalized for HF (3.5 % vs. 2.8 %, according to the 2-year Kaplan--Meier estimates; hazard ratio 1.27, 95 % CI = 1.07--1.51; p = 0.007). However, our results indicate that the BNP value, e' velocity and E/e' ratio do not change during sitagliptin use and, thus, sitagliptin may not be associated with an increased risk of HF or other serious adverse events. Therefore, we can conclude that both sitagliptin and voglibose can be safely used for patients with type 2 diabetes without an increased risk of worsening LV diastolic function.

Although thiazolidinediones activate the peroxisome proliferator-activated receptor γ (PPARγ) system and improve insulin sensitivity to reduce cardiovascular events \[[@CR26]\], they are reported to be associated with an increased risk of HF by augmentation of fluid retention \[[@CR27]\]. Interestingly, our data demonstrated that pioglitazone is an independent factor that affects the temporal changes in the e' velocity and E/e' ratio. The e' velocity significantly increased in both sitagliptin and voglibose groups if the patients who received pioglitazone were excluded. By contrast, the patients who used pioglitazone showed decreased e' velocity and increased E/e' ratio at the follow-up assessment. These data indicate that sitagliptin and voglibose might improve LV diastolic function by themselves, and that pioglitazone may attenuate the beneficial impact of these drugs on LV diastolic function. However, it is uncertain whether pioglitazone may worsen HF, because no patient who used pioglitazone was hospitalized with HF.

An excessive activity of circulating DPP4 was also found to be independently associated with subclinical LV dysfunction in T2DM patients \[[@CR28]\]. Decreased adiponectin levels were associated with LV diastolic dysfunction in patients with known or suspected coronary artery disease \[[@CR29]\]. Hibuse et al. reported that serum adiponectin level was elevated after a three-month treatment with sitagliptin \[[@CR30]\], and that abenefical effect of sitagliptin on LV diastolic dysfunction is expected. However, there was no significant increase in serum adiponectin level (0.5 ± 1.8, p = 0.092) after 24 weeks of treatment with sitagliptin in this study.

Sitagliptin was associated with an increase in GLP-1, but voglibose was not. Increased GLP-1 may augment diuresis and natriuresis by inhibiting sodium reabsorption from the proximal renal tubule \[[@CR31]\]. GLP-1 induces an endothelium-dependent vasorelaxation that is dependent on nitric oxide generation, and this may contribute to reduced peripheral vascular resistance \[[@CR32]\]. Clinical and experimental studies have shown that DPP-4i has a moderate blood pressure lowering effect \[[@CR33]\]. In this study, sitagliptin significantly lowered SBP, but voglibose did not (135 ± 16 mmHg vs. 128 ± 10 mmHg, respectively). There are many studies that demonstrate that reduced systolic blood pressure is associated with regression of LV mass, an increase in e' velocity and a reduction of HF events \[[@CR34]\]. Sitagliptin significantly decreased septal wall thickness in our study, but did not decrease LVMI after the 24-week treatment. In the LV hypertrophy rat model induced by isoproterenol infusion, we previously demonstrated that vildagliptin treatment was associated with a reduction in LV mass compared with the control group \[[@CR35]\]. However, the duration of exposure to the study drugs may not have been long enough to reverse the effects of years of diastolic dysfunction processes in patients. The present study does not exclude the possibility of either benefit or increased risk with a longer duration of sitagliptin therapy.

Owing to the limited sample size, this study is statistically underpowered {#Sec14}
--------------------------------------------------------------------------

However, there was almost no difference (much less than 0.8 cm/s; assumption) of the change in e' in the estimated value between the two groups in this study. So, even if the target number of cases had been achieved, based on current datasets, it would be unlikely that a statistically significant difference would have been obtained.

There are few data about the effect of anti-diabetic drugs on LV diastolic dysfunction. von Bibra et al. reported that 16 weeks of treatment with rosiglitazone improved LV diastolic dysfunction evaluated by Doppler echocardiography (e'; 7.9 cm/s → 8.9 cm/s, Δe' = 1.0 cm/s) \[[@CR20]\]. However, it remains unknown whether and how anti-diabetic drugs including DPP-4i improve LV diastolic function in patients with type 2 diabetes for now. Further investigation is needed in this area.

We evaluated diastolic function by measuring the e' velocity and the E/e' ratio at the septal side of the mitral annulus. Nagueh et al. reported that it is preferable to use the average e' velocity obtained from the septal and lateral sides of the mitral annulus. We evaluated the changes of e' and the E/e' (24 W-0 W) in this study, and our study population excluded patients with LV ejection fraction \< 50 % and myocardial infarction within the previous 24 weeks, thus single-site (septal e') measurements could be applicable.

Limitations {#Sec15}
-----------

We acknowledge several limitations in the present study. First, although this study was multicenter and randomized, the drug participation was open-label. Therefore, we used a biomarker, e' velocity, as the primary endpoint. Secondly, we did not measure plasma DPP-4 activity. The study of dos Santos et al. \[[@CR16]\] reported that positive correlations were observed between plasma DPP-4 activity and LV end-diastolic pressure and lung congestion in rats.

We did not know whether 50 mg sitagliptin could successfully inhibit plasma DPP-4 activity. We used 50 mg of sitagliptin, which is a standard starting dosage for this medication in Japan, however, outside of Japan, double this dose, i.e. 100 mg of sitagliptin, is generally used. A meta-analysis revealed that, despite the smaller sitagliptin dose of only 50 mg, a greater HbA1c reduction (−0.99 % versus placebo) was observed in Japanese than in non-Japanese patients \[[@CR36]\].

Thirdly, because of the small number of patients, we could not assess whether sitagliptin or pioglitazone can attenuate HF events in patients, as this study is statistically underpowered.

Fourth, 6-month treatment might be too short to improve the e' velocity or E/e' ratio. Fifth, echocardiographic studies were performed at each institution by experienced physicians or sonographers and the results were sent to the study center for analysis. These processes are close to those pertaining to real, clinical situations, and diastolic function echocardiographic parameters were supposed to be highly reproducible if performed by experts \[[@CR37]\], but inter-institution variability in the examinations may exist and may have influenced the results of this study.

To estimate the inter-institution variability is difficult because the number of cases per institution were too low to evaluate it.

Finally, selection criteria of this study population are strict. It is because we wanted to assess the net effect of DPP inhibitor on LV diastolic function in this study. It is necessary to note whether your patient corresponds to such a patient population or not.

Conclusion {#Sec16}
==========

Our trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with diabetes.
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:   Body mass index

BNP

:   Brain natriuretic peptide

DPP-4

:   Dipeptidyl peptidase IV
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:   Estimated glomerular filtration rate
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:   Gastric inhibitory peptide

GLP-1

:   Glucagon-like peptide-1
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:   High-sensitivity C-reactive protein
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:   8-hydroxy-2′-deoxyguanosine
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NGSP
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